• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1246540 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type! d! t$ f& B) |5 t
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
, {! ?" @" U+ r+ Author Affiliations
8 b# b' f, Y5 K8 i7 D8 }' r+ c% x! v. r) L* ~( Z# M8 w
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
+ S) U4 K8 D% Q- N2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan * V6 N1 }0 Y/ y( h
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
2 l# D$ P! h* {* o2 U; n& U2 v. t$ Y4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
: N) z7 j$ v% |* }5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
0 t6 i: K" h4 O/ q7 Y' q6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan 6 V8 V4 K  L2 X9 V% _& Q6 R' }
7Kinki University School of Medicine, Osaka 589-8511, Japan
5 q% a; m2 Q, ?. v# a8Izumi Municipal Hospital, Osaka 594-0071, Japan ( M) `. u) b1 o: `6 Z, B; k6 k
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan " c* B/ t9 v5 x5 X$ H3 H. @1 U
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp * m$ i! u$ O- z' j2 _
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. " i* |+ H. W* `

- I" ?$ ~+ ]' `: \& w( K3 {9 T
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type 3 o. _! b  `) w! z: K: W8 g

. B1 V  Z: T  V1 }0 DAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato 5 g' ~* s- }  r) R4 b8 W6 B

2 S2 v( N- Y7 h% k$ ?Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  6 A8 j; S4 u6 l* g

6 P2 P' n# ~$ ?! NPublished online on: Thursday, December 1, 2011 $ B  Q( j2 M! o( L- e
* M' m& Z$ x8 d# ]' l4 k
Doi: 10.3892/ol.2011.507
$ l- Q( E- Z' N& S  c$ t' T/ ?7 }" p& @+ v* g
Pages: 405-410
, S: B3 Q! p+ J& d$ j3 n
! t) o) h) M6 n5 J" G4 Q7 WAbstract:* r: d6 u# z- P! g, W# D% h  A
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.( ~& H% m! x1 c0 ?. S5 r0 R/ p

- N& a% G/ a, {9 k. d
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
0 [2 x! V( X- F3 }/ RF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 # d0 h5 s4 J' U9 h, i$ Y6 u
+ Author Affiliations
, i, Y! F) X. l6 L6 T1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
/ Q: y& F0 D; v8 s5 x( G$ u2 A7 q2Department of Thoracic Surgery, Kyoto University, Kyoto
  f% }: g1 V/ ?; W5 C3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan : O( s. Z" h: q; K# `, J
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp " _0 @' v" Q* f( w$ x+ b: [! ^. I
Received September 3, 2010.
6 m) x7 @% ^* }: I- O7 U$ |Revision received November 11, 2010.
8 i7 K2 ^% h6 a7 o9 ~Accepted November 17, 2010.
) N$ S7 u: B2 b6 dAbstract
2 o6 C4 T# |. K- r# y* qBackground: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. + E# M  o2 M& n8 E" p
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.   ?4 l3 s! q% P
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression. 1 O! [" C! g2 |* Q
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. + {# q; a0 y1 U$ r5 o5 n
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
5 D$ B! Y3 k9 h! o今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
) G% X4 v" u( @" i6 C
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
+ b( i5 Y; B# z% y0 ]+ Whttp://clinicaltrials.gov/ct2/show/NCT01523587
% h5 j3 h1 c. u" X1 T0 B! s$ r2 B" A) r) j- {1 J
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
) L" o$ y& w. m4 y) chttp://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 3 F& _! t$ Z' w8 k! _- x
6 R9 ^: X! n8 S- b
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。0 a* Z" x8 r, }* f
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53
' a5 t2 g/ Z5 T2 D1 y从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
, C; s# V7 }- K! K" _" M  x至今为止,未出 ...
" t( D% H3 X: o  z
没有副作用是第一追求,效果显著是第二追求。
' P2 N* z0 {! u# d不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表